The pooled incidence of CHOP, R-CHOP, and R-CDOP regimen was 1.0% (95% CI 0.00-0.01, <i>I<sup>2</sup></i> = 8%), 7.0% (95% CI 0.05-0.09, <i>I<sup>2</sup></i> = 64%) and 22.0% (95% CI 0.13-0.32, <i>I<sup>2</sup></i> = 87%) respectively.<h4>Conclusion</h4>PLD replacement, RTX addition and G-CSF administration were significant risk factors of IP for NHL patients received the CHOP-like chemotherapy. This evidence concerns the gene GPLD1 and non-Hodgkin lymphoma.